Optimisation des prospects
We optimize your lead compounds using expertise and data-driven decisions
The lead optimization stage marks the end of the drug discovery phase and the start of pharmaceutical or biological development. Insight into the absorption, distribution, metabolism, and excretion (ADME) is key to progressing your identified lead compounds after the hit to lead phase.
We support you in the further investigation of their target specificity, pharmacokinetic properties, bioavailability, and safety profiles by offering relevant in vitro and in vivo models, cost-efficient methods, and a key selection of assays using data-driven decision making.
Notre approche
We operate as a unified, committed, accessible team in solving your challenges quickly
Our study directors and technical specialists support you in the selection of your lead compounds with proof of effectiveness, decreased toxicity and absorption properties.
Making use of our portfolio of in vitro and in vivo models combined with in-depth and robust readouts from our state-of-the-art biomarker and imaging equipment, we can apply a data-driven and risk-based approach to this stage of your compound development.
Our team of experts consider your entire development journey when recommending cost-efficient solutions to reach your research milestones. We leverage our network of specialists to reduce your timeline and progress your compound more effectively to the patients that need it most.
Collaborez avec un expert pour faire progresser vos recherches thérapeutiques.
Collaborez avec notre équipe pour évaluer votre médicament et sa cible thérapeutique avec précision et expertise
Lead Optimization Techniques
InnoSer has experienced and dedicated study directors that manage and guide a proactive and effective study design along with a team of associates and bio technicians to help achieve high-quality service and results. With in-depth knowledge of our models and areas of therapeutic expertise we streamline the selection process to ensure robust results and fast progression. With our in vitro and in vivo facilities, we can support ADME and custom studies with the assessment of lead drug metabolites and relevant biomarkers. Through qualified partners we also offer pharmacometric assessment of lead-compounds. By estimating clinical pharmacokinetics, in-silico, early on in drug development this helps to assess clinical feasibility and reduce risk in your pipeline
We provide the following crucial services that are specific to the progression of your compound into the preclinical phase.
In Vivo Pharmacology
- Early assessment of DMPK properties
- Efficacy
- PK feasibility
- Metabolic stability
- Proof-of-Concept Studies
- MTD (Maximum Tolerated Dose) determination
- Dose frequency
- Dose response relations
- Therapeutic efficacy in in vivo disease model
In Vivo DMPK
- Assess route of administration
- Bioavailability
- Drug distribution
- DRF (Dose Range Finding)
- Preclinical efficacy
Toxicologie
- Single Dose Toxicity
- Repeated Dose Toxicity
- Toxicokinetics
Biomarker Assessment
-
Custom assay development and validation
- Meso Scale Discovery
- ELISA
- IHC
- Cytométrie en flux
- High Content Imaging
Imaging capabilities:
With our state-of-the-art equipment we can perform high content cellular imaging which supports compound prioritization and timely decision-making during the hit to lead and lead optimization phases of the drug development project.
Flow cytometry gives us the ability to analyze heterogeneous cell populations at specific time points making it a useful tool for testing drug-cell interactions.
Partnering with us will give you access to Meso Scale Discovery (MSD) testing services ideal for immunogenicity testing and multiplex biomarker assays
Explorer le pipeline de développement de médicaments
Accréditation AAALAC
InnoSer a obtenu l'accréditation AAALAC, ce qui témoigne de notre engagement en faveur d'une prise en charge et d'une utilisation responsables des animaux. AAALAC International est une organisation à but non lucratif qui promeut le traitement sans cruauté des animaux dans le domaine scientifique par le biais de programmes volontaires d'accréditation et d'évaluation. Les sites d'InnoSer aux Pays-Bas et en Belgique sont accrédités par l'AAALAC depuis 2016 et 2020, respectivement. Pour en savoir plus sur le programme d'accréditation de l'AAALAC, cliquez ici.
Bien-être animal
Les « 3R » ont une incidence sur tous les domaines, depuis les changements politiques et réglementaires jusqu’au développement et à l’adoption de nouvelles technologies et approches. C’est pourquoi InnoSer s’engage en permanence à suivre ces processus. Les mesures que nous mettons en œuvre optimisent notre capacité à remplacer, réduire et perfectionner l’utilisation des animaux et facilitent notre engagement envers ces principes dans le cadre de la recherche et du développement de médicaments.
info@innoserlaboratories.com
Liens rapides